Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.63 USD
-0.05 (-2.98%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.64 +0.01 (0.61%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ESPR 1.63 -0.05(-2.98%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
Other News for ESPR
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
Commit To Purchase Esperion Therapeutics At $1.50, Earn 36% Annualized Using Options
Market Outperform: Enhanced Insurance Coverage and FDA Approvals Propel Esperion’s Growth Potential
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL? (bempedoic acid) and NEXLIZET? (bempedoic acid and ezetimibe)
Esperion secures additional commercial, Medicare formulary coverage for NEXLETOL